| 前收盘价格 | 11.35 |
| 收盘价格 | 11.33 |
| 成交量 | 1,492,135 |
| 平均成交量 (3个月) | 2,000,540 |
| 市值 | 871,565,952 |
| 市盈率 (P/E TTM) | 46.84 |
| 预期市盈率 (P/E Forward) | 13.19 |
| 价格/销量 (P/S) | 8.49 |
| 股市价格/股市净资产 (P/B) | 7.35 |
| 52周波幅 | |
| 利润日期 | 12 Aug 2025 - 18 Aug 2025 |
| 营业毛利率 | 20.81% |
| 营业利益率 (TTM) | 51.49% |
| 稀释每股收益 (EPS TTM) | 0.250 |
| 总债务/股东权益 (D/E MRQ) | 0.41% |
| 流动比率 (MRQ) | 4.21 |
| 营业现金流 (OCF TTM) | -13.57 M |
| 杠杆自由现金流 (LFCF TTM) | -21.07 M |
| 资产报酬率 (ROA TTM) | 8.31% |
| 股东权益报酬率 (ROE TTM) | 19.87% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | CorMedix Inc. | 看涨 | 看涨 |
AIStockmoo 评分
0.5
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.50 |
|
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company’s focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 1.19% |
| 机构持股比例 | 37.18% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 20.00 (HC Wainwright & Co., 70.79%) | 购买 |
| 20.00 (Needham, 70.79%) | 购买 | |
| 中 | 18.50 (57.99%) | |
| 低 | 15.00 (D. Boral Capital, 28.10%) | 购买 |
| 平均值 | 18.00 (53.72%) | |
| 总计 | 4 购买 | |
| 平均价格@调整类型 | 14.55 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 30 Jun 2025 | 20.00 (70.79%) | 购买 | 12.32 |
| Needham | 24 Jun 2025 | 20.00 (70.79%) | 购买 | 15.72 |
| 07 May 2025 | 15.00 (28.10%) | 购买 | 11.68 | |
| D. Boral Capital | 23 Jun 2025 | 15.00 (28.10%) | 购买 | 16.56 |
| 06 May 2025 | 15.00 (28.10%) | 购买 | 11.16 | |
| RBC Capital | 20 Jun 2025 | 17.00 (45.18%) | 购买 | 13.61 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合